Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Journal of Hematology & Oncology|June 22, 2017
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repairAna-Alicia López-Iglesias, Ana B Herrero, Marta Chesi, et al.
Cancer Research|July 3, 2008
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivoConstantine S Mitsiades, Enrique M Ocio, Atanasio Pandiella, et al.
Cancer|March 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myelomaFredrik Schjesvold, Andrew Spencer, Yael C Cohen, et al.
Leukemia|April 6, 2023
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibodyMarc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
Leukemia|September 25, 2024
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)María-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
American Journal of Hematology|June 18, 2026
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)Heinz Ludwig, Evangelos Terpos, Francesca Gay, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
The New England Journal of Medicine|January 8, 2025
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple MyelomaYael C Cohen, Hila Magen, Moshe Gatt, et al.
Leukemia & Lymphoma|August 4, 2023
Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa studyLaura Rosiñol Dachs, Carmen Montes Gaisán, Gabriela Bustamante, et al.
Blood|October 27, 2015
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MMMaría-Victoria Mateos, Joaquín Martínez-López, Miguel-Teodoro Hernández, et al.
Pageof 13